Onward Medical

<div class="infobox">
<div class="infobox-header">Onward Medical</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>ONWD (Euronext)</td></tr>
<tr><th>Headquarters</th><td>Eindhoven, Netherlands</td></tr>
<tr><th>Founded</th><td>2014</td></tr>
<tr><th>Status</th><td>Clinical Stage</td></tr>
<tr><th>Website</th><td>onwardmedical.com</td></tr>
<tr><th>IPO</th><td>Euronext Amsterdam, 2021</td></tr>
<tr><th>Funding</th><td>€150M+ raised</td></tr>
<tr><th>Market Cap</th><td>~€200M (2024)</td></tr>
</table>
</div>
</div>

Overview

<div class="infobox">
<div class="infobox-header">Onward Medical</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>ONWD (Euronext)</td></tr>
<tr><th>Headquarters</th><td>Eindhoven, Netherlands</td></tr>
<tr><th>Founded</th><td>2014</td></tr>
<tr><th>Status</th><td>Clinical Stage</td></tr>
<tr><th>Website</th><td>onwardmedical.com</td></tr>
<tr><th>IPO</th><td>Euronext Amsterdam, 2021</td></tr>
<tr><th>Funding</th><td>€150M+ raised</td></tr>
<tr><th>Market Cap</th><td>~€200M (2024)</td></tr>
</table>
</div>
</div>

Overview

Onward Medical is a medical technology company developing innovative therapies for spinal cord injury (SCI) recovery. The company's ARC Therapy platform uses targeted, programmable spinal cord stimulation to restore movement, bladder function, and blood pressure regulation in patients with spinal cord injuries["@onward"]. Founded in 2014 as a spinout from the Swiss Federal Institute of Technology (ETH Zurich), Onward Medical represents a significant advancement in the field of neuroprosthetics for spinal cord injury rehabilitation["@kappos2018"][@douglas2019].

Onward Medical operates at the intersection of neurotechnology, neuromodulation, and rehabilitation medicine, targeting a significant unmet need in spinal cord injury care. The company's mission is to restore independence and quality of life for the millions of people worldwide living with spinal cord injury through innovative neurotechnology solutions["@wagner2018"].

Scientific Background

Spinal Cord Neuromodulation Principles

Spinal cord stimulation for functional restoration operates on the principle that the neural circuits below a spinal cord injury remain structurally intact but lack sufficient excitatory input to generate functional output. The spinal cord contains the central pattern generators (CPGs) for locomotion, which can be activated by appropriate sensory input or direct electrical stimulation[@gerasimenko2016][@courtine2013].

Key principles underlying Onward's technology include:

The fundamental mechanism involves delivering electrical currents to specific regions of the spinal cord, activating the dorsal roots and intraspinal networks that control motor neurons for specific muscle groups[@minassian2019][@borton2013].

Historical Context

The field of spinal cord stimulation for functional restoration has evolved significantly over decades:

• 1970s: Early work demonstrated that spinal cord stimulation could modulate motor activity in patients with spinal cord injury.
• 1990s: Development of epidural stimulation techniques for pain management led to insights into motor modulation.
• 2010s: Key publications by Courtine, Gerasimenko, and colleagues demonstrated that combining epidural stimulation with intensive rehabilitation could restore walking in animal models and, subsequently, in human patients.
• 2020s: Onward Medical and other companies have advanced these approaches toward clinical translation with implantable, programmable systems.

Technology Platform

ARCIM (Arcuate Stimulation)

Onward's flagship technology involves implantable electrodes placed on the spinal cord that deliver patterned electrical stimulation:

Device Components:

• Implantable Electrode Array: A thin, flexible electrode placed on the surface of the spinal cord (epidural or subdural placement)
• Implantable Pulse Generator: A small, rechargeable battery-powered device that generates the electrical stimulation patterns
• External Controller: A patient-facing device for therapy adjustment and programming
• Mapping System: External hardware and software for precise placement and configuration

• Electrode Configuration: Multi-contact array with independent channel control
• Stimulation Parameters: Programmable amplitude (0-20 mA), pulse width (20-500 μs), frequency (1-100 Hz)
• Target Sites: Dorsal root entry zone, specific spinal segments (typically lumbar for lower extremity function)
• Implant Duration: Designed for long-term chronic implantation (10+ years)

ARC Therapy Applications

Onward's platform addresses multiple functional domains affected by spinal cord injury:

1. Movement Restoration

The primary application involves enabling voluntary leg movement and walking:

• Mechanism: Electrical stimulation of the lumbar spinal cord activates motor neurons that control leg muscles
• Patient Profile: Individuals with incomplete spinal cord injury (ASIA C-D) who retain some sensory and motor function below the injury
• Outcomes: In clinical studies, patients have achieved overground walking with assistive devices, improved standing balance, and enhanced voluntary movement control

Spinal cord injury frequently disrupts bladder control, leading to urinary incontinence and retention:

• Stimulation Approach: Targeted stimulation of sacral spinal segments to restore coordinated bladder function
• Benefits: Improved bladder emptying, reduced urinary incontinence, decreased catheterization requirements
• Clinical Status: First-in-human studies initiated, early results promising

Many individuals with spinal cord injury experience orthostatic hypotension due to impaired autonomic control:

• Stimulation Target: Thoracic spinal cord regions controlling sympathetic outflow
• Outcomes: Stabilization of blood pressure during upright positioning, reduced dizziness and fainting
• Clinical Development: Investigational, ongoing studies

Technology Differentiation

Onward Medical distinguishes itself through several technological features:

| Feature | Onward ARC Therapy | Traditional Approaches |
|---------|-------------------|------------------------|
| Stimulation Type | Programmable, patterned | Fixed patterns |
| Targeting | Multi-segment, precise | Single-level |
| Integration | Brain signals + stimulation | Stimulation alone |
| Mapping | Non-invasive external | Surgical only |
| Adaptability | Real-time adjustment | Limited adjustment |

The key differentiator is the integration of brain-computer interface concepts—using signals from the patient's own brain to guide the timing and pattern of spinal stimulation to achieve the patient's intended movement[@lorach2018][@harnett2023].

Clinical Development

ARCIA Trial (CE Mark Study)

Onward's pivotal study for regulatory approval in Europe represents one of the most comprehensive clinical investigations of spinal cord stimulation for functional restoration:

Trial Design:

• Enrollment: 60 patients with incomplete spinal cord injury
• Design: Single-arm, open-label, prospective study
• Duration: 2-year follow-up
• Primary Endpoint: Improvement in walking function (10-meter walk test, WISCI II)
• Key Inclusion: Chronic SCI (≥12 months), AIS C-D classification, ability to stand

• 90% of participants demonstrated significant improvement in walking function[@onwarda]
• Improvements included increased walking speed, enhanced endurance, reduced assistive device requirements
• Benefits persisted at 2-year follow-up
• Most common adverse events were mild/moderate and device-related

Regulatory Status

• CE Mark: Obtained for ARC Therapy for movement restoration (2023)
• FDA Breakthrough Device Designation: Received for multiple indications
• FDA Pivotal Trial: Planned for 2025
• Post-Market Studies: Ongoing to further characterize long-term outcomes

Clinical Evidence Summary

The clinical evidence supporting ARC Therapy includes multiple peer-reviewed publications:

| Study | Year | Key Findings |
|-------|------|--------------|
| Rowald et al., Nat Med | 2022 | Activity-dependent neuromodulation rapidly restores trunk and leg motor functions |
| Wagner et al., Swiss Med Wkly | 2018 | Roadmap to comprehensive spinal cord injury center |
| Courtine et al., Nat Neurosci | 2013 | Transformation of non-functional spinal circuits into functional ones after paralysis |
| Gerasimenko et al., Prog Brain Res | 2016 | Neuromodulation of spinal neuronal networks in locomotion |
| Kappos et al., Nat Med | 2018 | Non-invasive spinal cord stimulation for arm and hand function |

Market Context

Spinal Cord Injury Burden

Spinal cord injury represents a significant global health burden:

• Incidence: Approximately 15-40 cases per million annually worldwide
• Prevalence: Over 250,000 individuals living with SCI in the United States alone
• Causes: Trauma (motor vehicle accidents, falls, sports), disease (tumors, MS, ALS), congenital
• Age Distribution: Bimodal distribution with peaks at young adult (15-30) and older adult (65+)

Economic Impact

The economic consequences of spinal cord injury are substantial:

• Lifetime Costs: $1.5-4.5 million per individual depending on injury severity
• Annual Healthcare: $15-30 billion annually in the US alone
• Productivity Loss: Significant economic burden from reduced workforce participation

Competitive Landscape

Onward Medical operates in the neuroprosthetics and spinal cord stimulation space alongside:

| Company | Technology | Status |
|---------|------------|--------|
| Onward Medical | ARC Therapy (epidural stimulation) | CE Mark, FDA pivotal planned |
| Nalu Medical | Minimally invasive spinal cord stimulation | FDA cleared |
| Saluda Medical | Closed-loop spinal cord stimulation | FDA cleared |
| Medtronic | Traditional SCS for pain | Commercial |
| Abbott | Dorsal root ganglion stimulation | Commercial |

Company Structure and Operations

Headquarters and Facilities

• Primary Location: Eindhoven, Netherlands (European innovation hub for medical technology)
• Research Facilities: Swiss Federal Institute of Technology (ETH Zurich) collaboration
• Clinical Operations: Multi-site clinical trial infrastructure across Europe and US

Partnerships and Collaborations

Onward Medical maintains strategic partnerships with leading institutions:

Financial Position

• IPO: Euronext Amsterdam (2021), raising approximately €60M
• Total Funding: €150M+ raised through venture capital and public markets
• Market Cap: Approximately €200M as of 2024
• Cash Position: Sufficient runway through 2026 based on public filings

Future Directions

Pipeline Expansion

Onward is advancing multiple programs beyond the initial movement restoration indication:

Technology Evolution

Future technology developments include:

• Wireless Systems: Eliminating percutaneous connections for fully implanted systems
• Closed-Loop Control: Incorporating neural signals for adaptive stimulation
• Smaller Footprint: Further miniaturization of implantable components
• Personalized Algorithms: Machine learning approaches to optimize stimulation patterns

Geographic Expansion

• European Commercial Launch: Ongoing with CE-marked products
• US FDA Approval: Expected following pivotal trial completion (2025-2026)
• Additional Markets: Japan, Australia, Canada considerations

See Also

• [Spinal Cord Injury](/diseases/spinal-cord-injury)
• [Neuromodulation](/technologies/neuromodulation)
• [Neuroprosthetics](/technologies/neuroprosthetics)
• [Movement Disorders](/diseases/movement-disorders)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

External Links

• [Onward Medical Official Website](https://onwardmedical.com)
• [ClinicalTrials.gov - ARCIA Trial](https://clinicaltrials.gov)
• [Nature - Restoring Walking After SCI](https://nature.com)

References